NCT05204173Unknown2 期
Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- 1-year survival rate
研究概览
简要总结
In this phase 2 study, we combined sintilimab, paclitaxel and S-1 as regimen to treat gastric cancer patients with peritoneal metastasis. We are aim to estimate the efficacy and safety of this regimen in the phase 2 study.
详细描述
Gastric cancer patients enrolled in this a phase 2 study received sintilimab (200mg intravenously on day 1), paclitaxel (PTX) (20 mg/m2 intraperitoneally and 50 mg/m2 intravenously on days 1 and 8) plus oral S-1 (80 mg/m2 for 14 consecutive days) every 3 weeks. The primary endpoint is 1-year survival rate. Secondary endpoints are adverse events, R0 resection rate, 3-year overall survival (OS), and 3-year progressive free survival. Adverse events are monitored and graded according to the Common Terminology Criteria for Adverse Events version 4.0.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed gastric adenocarcinoma;
- •Peritoneal metastases from gastric cancer requiring definitive diagnosis by laparoscopy, and without gastric outflow tract obstruction and intestinal obstruction;
- •Written (signed) informed consent;
- •Age ≥ 18 years at registration;
- •Eastern Cooperative Oncology Group (ECOG) score ≤ 2;
- •Expected life expectancy > 3 months;
- •Adequate bone marrow, liver, and renal functions. absolute neutrophil count of ≥1.5×109/L; absolute neutrophil count of ≥1.5×109/L; platelet count of ≥100×109/L; hemoglobin ≥90g/L; bilirubin of <1.5×upper limit of normal [ULN]; alanine aminotransferase and aspartate aminotransferase of <2.5×ULN; serum creatinine of ≤1.5×ULN; creatinine clearance of >50 mL/min; TSH ≤1×ULN (if abnormal, T3 and T4 levels should be inspected at the same time, if T3 and T4 levels are normal, they can be included in the group); APTT ≤1.5×ULN and INR ≤1.5×ULN; myocardial enzymogram ≤1×ULN.
排除标准
- •Confirmed of evidence of distant metastasis other than peritoneal metastasis (e.g.liver metastasis, lung metastasis, para-aortic lymph node metastasis, etc.);
- •During pregnancy, within 28 days of post parturition, or during lactation;
- •Synchronous or metachronous (within 5 years) malignancies.
- •Severe mental disease, uncontrolled epilepsy, or central nervous system disease;
- •Clinically severe (i.e. active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or arrhythmia requiring drug intervention, or a history of myocardial infarction in the last 12 months;
- •Upper gastrointestinal obstruction or abnormal physiological function or malabsorption syndrome may affect S-1 absorbers;
- •Known peripheral neuropathy (> NCI-CTC AE 1). However, patients with only disappearance of deep tendon reflex (DTR) need not be excluded;
- •Patients on steroid or immunosuppressant treatment after organ transplant;
- •Patients with severe uncontrolled recurrent infections or other severe uncontrolled concomitant disease;
- •Moderate or severe renal damage [creatinine clearance ≤ 50 ml/min], or serum creatinine > upper limit of normal (ULN), 115 μmol/L;
- •Known dihydropyrimidine dehydrogenase (DPD) deficiency;
- •Anaphylaxis to paclitaxel or any research drug ingredient.
- •Active autoimmune disease or history of refractory autoimmune disease; Subjects with hypothyroidism requiring only hormone replacement therapy and skin diseases without systemic treatment (such as vitiligo, psoriasis or alopecia) can be selected;
- •HIV antibody positive, active hepatitis B or C (hepatitis B: HBsAg positive and HBV DNA ≥10 copies/ml; hepatitis C: HCV antibody and HCV-RNA positive, requiring antiviral treatment at the same time);
- •Steroid or other systemic immunosuppressive therapy was used 14 days before admission, excluding local or physiological doses of systemic glucocorticoids (eg. no more than 10mg/day of prednisone or other glucocorticoids of equivalent dose) by nasal spray, inhalation or other routes, or hormones used to prevent allergy of contrast agents;
- •Uncontrolled arrhythmia and myocardial infarction within 12 months before admission or active tuberculosis.
研究组 & 干预措施
Intraperitoneal
Experimental
Sintilimab 200mg intravenous (IV) infusion on day 1, PTX 50 mg/m2 IV and PTX 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days every 3 weeks.
干预措施: sintilimab, paclitaxel and S-1 (Drug)
结局指标
主要结局
1-year survival rate
时间窗: 12 months
次要结局
- R0 resection rate(24 months)
- 3-year overall survival (OS)(36 months)
- Number of participants experiencing clinical and laboratory adverse events (AEs)(24 months)
- 3-year progressive free survival (PFS)(36 months)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction AdenocarcinomaAdvanced Gastric and Gastro-esophageal Junction AdenocarcinomaNCT04140318Chinese Academy of Medical Sciences60
尚未招募
2 期
Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical StudyGastroEsophageal CancerAdenocarcinomaGastric CancerNCT06241469Wu Jun40
招募中
2 期
Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell CarcinomaOral Squamous Cell CarcinomaOropharyngeal Squamous Cell CarcinomaNCT04718415Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University51
招募中
2 期
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeMMalignant Peritoneal Mesothelioma, AdvancedNCT06543069Cancer Institute and Hospital, Chinese Academy of Medical Sciences28
已完成
1 期
Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT04072679Chinese Academy of Medical Sciences50